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Background: Chemokine and chemokine receptors play an essential role in tumorigenesis. Although
chemokine-associated single nucleotide polymorphisms (SNPs) are associated with various cancers, their impact on
prostate cancer (PCA) among men of African descent is unknown. Consequently, this study evaluated 43
chemokine-associated SNPs in relation to PCA risk. We hypothesized inheritance of variant chemokine-associated
alleles may lead to alterations in PCA susceptibility, presumably due to variations in antitumor immune responses.
Methods: Sequence variants were evaluated in germ-line DNA samples from 814 African-American and Jamaican
men (279 PCA cases and 535 controls) using Illumina’s Goldengate genotyping system.
Results: Inheritance of CCL5 rs2107538 (AA, GA+AA) and rs3817655 (AA, AG, AG+AA) genotypes were linked with a
34-48% reduction in PCA risk. Additionally, the recessive and dominant models for CCR5 rs1799988 and CCR7
rs3136685 were associated with a 1.52-1.73 fold increase in PCA risk. Upon stratification, only CCL5 rs3817655 and
CCR7 rs3136685 remained significant for the Jamaican and U.S. subgroups, respectively.
Conclusions: In summary, CCL5 (rs2107538, rs3817655) and CCR5 (rs1799988) sequence variants significantly
modified PCA susceptibility among men of African descent, even after adjusting for age and multiple comparisons.
Our findings are only suggestive and require further evaluation and validation in relation to prostate cancer risk and
ultimately disease progression, biochemical/disease recurrence and mortality in larger high-risk subgroups. Such
efforts will help to identify genetic markers capable of explaining disproportionately high prostate cancer incidence,
mortality, and morbidity rates among men of African descent.
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Prostate cancer (PCA) is one of the leading causes of
cancer and cancer-related deaths among men in the U.S.
and Caribbean and its disparities are well documented
[1-3]. From 2003–2007, the average annual PCA inci-
dence rates (229.4 per 100,000) and mortality (54.2 per
100,000) rates among African-American men were 1.6-
and 2.4-fold higher than US Caucasian men, respect-
ively. According to the 2008 World age-standardized
death rates for Caribbean men (26.3/100,000) were 2.65-
fold higher than all U.S. men (9.9/100,000) [3]. Despite
its public health burden, the etiology of PCA is not com-
pletely elucidated. Established risk factors for PCA in-
clude older age, black race, and family history of the
disease. Other plausible contributors of prostate tumori-
genesis include endocrine, lifestyle, environmental, and
genetic factors as well as imbalances in inflammatory,
immune surveillance, and angiogenesis pathways.
Among the inflammatory factors, chemokines (e.g.,
CC, CXC, XCL, and C-X3-C) play a pivotal role in
chemotaxis, leukocyte trafficking, lymphocyte develop-
ment, angiogenesis, host response to infection, inflam-
matory processes, tumor development, migration and
metastasis. Chemokines mediate their actions through 7-
transmembrane, G protein coupled receptors and serve
three major physiological functions. First, they play fun-
damental roles in the maturation, homeostasis and func-
tion of the immune system, as well as facilitate the
trafficking of memory T cells, lymphocytes, monocytes,
and neutrophils to the inflammatory site. Secondly, they
display chemotactic activity for lymphocytes, monocytes,
and neutrophils. Lastly, they attract cancer cells and che-
mokine receptor bearing cells and have effects on endo-
thelial cells involved in angiogenesis regulation. Several
CXC chemokines are potent angiogenesis promoters (i.e.,
CXCL1, 2, 3, 5, 6, 7) [4-6]; whereas, others inhibit angio-
genesis (i.e., CXCL4, 9, 10, 11) [7].
Genetic alterations and altered expression of chemo-
kines and their receptors have been linked to the sus-
ceptibility, development and survival of numerous
cancers, including prostate cancer [8-12]. In fact, over
expression of CCL5 and CCR5 has been detected in
prostate tissue and associated with aggressive disease,
presumably by triggering leukocyte production and
promoting cell survival, proliferation, invasion and me-
tastasis [13-15]. Coding and regulatory regions of a
number of chemokine-associated genes directly influ-
ence chemokine production and have been demon-
strated to modulate the risk of developing various
cancers [10,16-21]. The CCL5 -403A allele conferred
an increased risk of prostate, oral and pancreatic can-
cer [18,22,23]. Furthermore, inheritance of the CCR7
rs3136685 AG+AA or CCR7 rs3136687 (AG, AG+AA)
genotypes was associated with a 60-62% reduction inmultiple myeloma (MM) and chronic lymphocytic
leukemia, respectively [19,21]. Unfortunately, these pre-
viously mentioned studies focused on single SNPs in re-
lation to cancer primarily among men of European
descent. Consequently, the influence of individual CCL5,
CCR5, CCR7 and other chemokine associated sequence
variants on PCA is unknown among men of African
descent.
Thus, the current study evaluated main effects of 43
chemokine-related sequence variants in relation to pros-
tate cancer susceptibility among men of African Descent
from the U.S. and Jamaica. Preliminary findings from
this study will guide future studies that seek to find im-
portant diagnostic, tumor classification and prognostica-
tion indicators of PCA in high-risk subgroups.
Methods
Study population
The current study consisted of 279 cases and 535 con-
trols obtained from two independent case control study
sets, as summarized in Table 1, Additional file 1, and
Additional file 2. These studies include the Prostate
Cancer Clinical Outcome Study (PC2OS) at the Univer-
sity of Louisville and the Prostate Cancer Study in Ja-
maica at the University of the West Indies, Mona
Campus. For the PC2OS study, 603 unrelated male resi-
dents were recruited from the Washington, D.C. and
Columbia, SC areas through the Howard University
Hospital (HUH) Division of Urology or related PCA
screening programs between 2001 and 2005. This popu-
lation of men of African descent (i.e., self-reported
African Americans, East African Americans, West
African Americans, and Afro-Caribbean Americans)
consisted of 170 incident PCA cases and 433 controls
(Additional file 1). Between March 2005 and July 2007,
two hundred twenty-one unrelated Jamaican men were
recruited and consecutively enrolled into the prostate
cancer case–control study (109 prostate cancer cases,
102 controls) during their first time visit at urology
clinics (Additional file 2). Details on case and control
ascertainment and inclusion criteria for both sub-
populations have ben detailed elsewhere [24,25]. All
study participants provided written informed consent for
participation in genetic analysis studies under a protocol
approved by the Howard University, the HUH Division
of Urology, and the University of Louisville Institutional
Review Board (#201.07).
Criteria for chemokine and chemokine receptor gene and
SNP selection
Chemokine-associated genes and SNPs were selected
using one or more of following criteria: (1) epidemio-
logical or molecular biological evidence from published
reports indicating a relationship between the SNP/gene
Table 1 Baseline Characteristics among men of African
Descent from the US & Jamaica
Characteristics Cases Controls p value†
Number of Participants, n 279 535 —
Age at enrollment
(yrs), Median (range)
67 (45–91) 53 (27–89) <0.0001
Family History of
Prostate Cancer, n (%)
Yes 35 (16.1) 21 (12.5) 0.316
No 182 (83.9) 147 (87.5)
Missing 62 (22.2) 367 (68.6)
PSA (ng/ml), median 11.7 (0.01-10,000) 0.9 (0.0-4.0) <0.0001
PSA (ng/ml), n (%)
< 4 37 (13.8) 517 (99.8) <0.0001
≥ 4 231 (86.2) 1 (0.2)
Missing 11 (0.04) 17 (0.03)









Global WAA, mean (SD) 0.79 (0.25-0.94) 0.767 (0.25-0.95) 0.107
Abbreviations: PSA, prostate specific antigen; WAA, West African Ancestry;
†Differences in family history or PSA frequencies between cases and controls
were tested by a Chi-square test of homogeneity; differences in median age
(yrs) and Global West African Ancestry between cases and controls were
tested using the Wilcoxon sum Rank test.
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diseases; (2) commonly studied loci; (3) marked dispar-
ities in genotype frequency comparing men of African
descent to their Caucasian counterparts (i.e., ±10%
change); (4) evidence demonstrating a link with altera-
tions in mRNA expression/stability or protein expres-
sion/structure or function using in silico tools (e.g.,
SNPinfo) or published reports (http://snpinfo.niehs.nih.
gov/snpfunc.htm); and (5) a minor allele frequency ≥1%
reported in the National Center for Biotechnology Infor-
mation (NCBI) Entrez SNP, (www.ncbi.nlm.nih.gov). On
average, a majority of the SNPs had minor allele fre-
quencies ranging from 26-27%. However, five SNPs with
allele frequencies greater than 1% but less than 5% were
included in the analysis to explore whether rare SNPs
would lead to substantial gains in effect sizes (i.e., 2–3
fold increases in risk) and contribute to missing genetic
heritability [26,27]. The SNPinfo webserver enabled us
to annotate and/or predict the functional consequence
of chemokine-associated sequence variants on alterna-
tive alleles, as summarized in Additional file 3.Genetic analysis of variant chemokine-associated SNPs
In order to evaluate and validate chemokine-related
markers as predictors of PCA risk, de-identified germ-
line DNA from PCA cases and disease-free individuals
were genotyped using a custom Illumina GoldenGate
Genotyping assay with VeraCode Technology and
BeadXpress reader, according to the manufacturer’s
instructions [28].
Ancestry markers
Cases and controls were also genotyped with a set of
100 genome-wide ancestry informative markers to cor-
rect for potential population stratification among our
admixed population of self-reported African-Americans,
West African-Americans, East African-Americans, Afro-
Caribbean-Americans, as previously described [29,30].
Study participants were grouped from lowest to highest
genetic West African Ancestry, with scores ranging from
0-100%. These 100 markers were assembled using DNA
from self-identified African-Americans (Coriell Institute
for Medical Research, n = 96), Yoruban West Africans
(HapMap, n = 60), West Africans (Bantu and Nilo Sa-
haran speakers, n = 72), Europeans (New York City, n =
24), and CEPH Europeans (HapMap Panel, n = 60), as
previously reported [30]. Individuals with a West African
ancestry (WAA) score ≥25% and available chemokine-
associated data were included in the final analysis.
Quality control assurance and data management of
genotype data
At the onset of the project, allelic discrimination focused
on chemokine associated SNPs among men of African
Descent. To minimize misclassification bias, laboratory
technicians were blinded to the case status of study par-
ticipants. Each batch of up to 96 samples included four
non-DNA template controls and eight duplicate sam-
ples, enabling us to calculate the percent contamination
(i.e., 0%) and concordance rates (i.e., 100%) per batch.
Genotype call rates were calculated separately for each
SNP and study participant. Lastly, we tested whether the
distribution of the genotypes among disease-free indivi-
duals had significant departures from the Hardy-
Weinberg equilibrium (HWE).
Prior to performing marker statistics, we excluded
subjects who had genotype call rates that were <90%. To
ensure high quality data, nine SNPs were excluded from
the final analysis if: the distribution of the genotypes
among controls deviated substantially from the Hardy-
Weinberg Equilibrium, using a conservative significance
level cut-off value of P ≤ 0.005 (n = 1); they had a minor
allele frequency <1% (n = 6); or low genotype call rates
<95% (n = 2). Following data clean-up, 43 chemokine-
related SNPs were included in the final analysis consist-
ing of 814 men of African descent (279 cases, 535
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ment was performed using Golden Helix’s SNP Variation
Software 7.0 (Bozeman, MT).
Statistical analysis for single gene effects
Univariate and multivariate analyses were used to evalu-
ate chemokine-associated SNPs among men of African
descent in relation to prostate cancer risk. To assess
whether inheritance of one or more chemokine allele(s)
influence the risk of developing PCA, we tested for sig-
nificant differences in the distribution of homozygous
major, heterozygous, or homozygous minor genotypes
between cases and controls using the chi-square test of
homogeneity. The association between PCA risk and
selected polymorphic genes, expressed as odds ratios
(ORs) and corresponding 95% confidence intervals (CIs),
were estimated using unconditional multivariate LR
models adjusted for age. LR analyses for genetic variants
and PCA development were conducted using the major
or common genotype as the referent category. All ana-
lyses were conducted using SAS 9.3 (SAS Institute Inc.,
Cary, NC) and SNP Variation Software 7.0 (GoldenHe-
lix, Bozeman, MT). Statistical significance was assessed
using a False Discovery Rate cut-off of 0.05, in order to
adjust for multiple comparisons.
Statistical power for single gene effects
We conducted calculations to determine the statistical
power of our sample to detect significant relationships
between chemokine-related genotypes and PCA devel-
opment. The expected risk estimates of our study can be
estimated by specifying values for a number of para-
meters, including a minor allele frequency of at least
26.5%, National Cancer Institute's estimate of PCA dis-
ease prevalence (0.74%), number of cases (n = 279), and
number of controls (n = 535). We assumed the causal
SNP was in complete linkage disequilibrium with the
predisposing variant (r2 = 1.0). Based on our sample size
for the total population, U.S. and Jamaican men, we had
>80% power to detect genetic markers with odds ratios
(ORs) of ≥1.5, ≥1.55, and ≥2.0 for PCA risk, respectively,
for minor allele frequency of at least 26.5%, assuming a
co-dominant genetic model with 1 degree of freedom
(df). Power calculations were performed using Power for
Genetic Association Version 2 Software [31].
Results
Population description
The demographic and other pertinent characteristics of
cases and controls for the entire study population and
each study center are summarized in Table 1, Additional
file 1, and Additional file 2. Overall, men diagnosed with
prostate cancer were 14 years older and had higher PSA
levels than controls (P < 0.0001). Disease-free men fromJamaica were about 9 years older than U.S. controls;
however, there were no significant differences in family
history of prostate cancer or PSA levels for these
disease-free subgroups. Jamaican cases had 7 fold higher
PSA levels (P < 0.0001) and slightly higher median Glea-
son scores (P = 0.018) compared to cases from the U.S.
There were no differences in the distribution of family
history of prostate cancer comparing: (1) cases to con-
trols from the total population (P = 0.316) (Table 1),
U.S. alone (P = 0.592) (Additional file 1), or Jamaica
alone (P = 0.272) (Additional file 2); and (2) controls
(P = 0.757) or cases (P = 0.830) comparing the two study
centers (data not shown).
Prevalence of minor alleles/genotype frequency
comparing men of African Descent from the U.S. and
Jamaica
Overall, the chemokine-related SNPs were fairly com-
mon among disease-free individuals from the entire
sub-population of U.S. and Jamaica, with average minor
frequencies of 26-27% and a standard deviation of 14%,
respectively (data not shown). Thirty-eight SNPs had
minor allele frequencies ≥5%. For exploratory purposes,
five rare SNPs (CCR9 rs12721497, CCL17 rs11076191,
CCL11 rs4795896, CCL21 rs11574916, CXCL12
rs1801157) were analyzed with minor allele frequencies
ranging between 1.5-4.9%. The minor allele frequency
comparing controls from the U.S. and Jamaica were
strongly correlated (R2 = 0.957). Only 5 out of the 43
SNPs analyzed were discordant comparing men of
African descent from the U.S. to men from Jamaica
(P < 0.0487), namely CCL17 rs11076191, CCL21
rs11574916, CCR7 rs3136685, CCR7 rs3136687, and
CCR9 rs12721497.
Relationship between chemokine sequence variants and
prostate cancer risk
Among all men of African descent, five sequence variants
were significantly associated with the risk of developing
prostate cancer, as summarized in Table 2. Possession of
the CCL5 rs2107538 GA+AA (ORunadjusted = 0.59; 95%CI =
0.44, 0.80) or CCL5 rs3817655 GA+AA (ORunadjusted =
0.54; 95%CI = 0.40, 0.74) genotype was linked with a
41-46% reduction in PCA risk in the unadjusted
LR models. These effects remained significant for
both SNPs after adjusting for age (CCL5 rs2107538:
ORadjusted = 0.66; 95%CI = 0.46, 0.96) and CCL5
rs3817655: ORadjusted = 0.56; 95%CI = 0.39, 0.81). The re-
cessive genetic model for CCR5 rs1799988 (ORadjusted =
1.52; 95%CI = 1.02, 2.26) as well as the dominant genetic
models for CCR7 rs3136685 (ORadjusted = 1.66; 95%CI =
1.09, 2.54) and CCR7 rs3136687 (ORadjusted =1.14; 95%
CI = 1.12, 1.16) were associated with a significant 1.14-
1.66 fold increase in PCA risk within the age adjusted
Table 2 Association between chemokine associated SNPs and prostate cancer risk among men of African descent
Genes dbSNP ID Location Genotype Cases n (%) Controls n (%) Unadjusted Adjusted P-value P-trend FDR
predicted
function†
OR (95%CI) OR (95%CI)
CCR5 rs1799988 5’UTR AA 85 (30.7) 194 (36.7) 1.00 (referent) 1.00 (referent) 0.005 0.0039 0.0682
TFBS AG 107 (38.6) 227 (43.9) 1.08 (0.76, 1.52) 0.83 (0.55, 1.25) 0.676
GG 85 (30.7) 108 (20.4) 1.80 (1.23, 2.63) 1.38 (0.87, 2.17) 0.003
AG+GG 192 (69.3) 335 (63.3) 1.31 (0.96, 1.78) 1.01 (0.70, 1.46) 0.09 0.4823
GG vs (AA+AG) 1.73 (1.24, 2.40) 1.52 (1.02, 2.26) 0.0013 0.0494
CCL5 rs2107538 5' near gene GG 111 (39.8) 150 (28.1) 1.00 (referent) 1.00 (referent) 0.002 0.001 0.0493
TFBS GA 124 (44.4) 270 (50.6) 0.62 (0.45, 0.86) 0.72 (0.49, 1.06) 0.004
AA 44 (15.8) 114 (21.4) 0.52 (0.34, 0.80) 0.53 (0.32, 0.89) 0.003
GA+AA 168 (60.2) 384 (71.9) 0.59 (0.44, 0.80) 0.66 (0.46, 0.96) 0.0007 0.015
AA vs (GG+GA) 0.83 (0.57, 1.20) 0.74 (0.47, 1.16) 0.057 0.4735
CCL5 rs3817655 Intron 2 GG 114 (41.0) 147 (27.5) 1.00 (referent) 1.00 (referent) 0.004 0.002 0.019
TFBS GA 115 (41.4) 278 (52.0) 0.53 (0.38, 0.74) 0.57 (0.38, 0.84) 0.0002
AA 49 (17.6) 110 (20.5) 0.57 (0.38, 0.87) 0.54 (0.32, 0.89) 0.0009
GA+AA 164 (59.0) 388 (72.5) 0.54 (0.40, 0.74) 0.56 (0.39, 0.81) 0.0001 0.0038
AA vs (GG+GA) 0.83 (0.57, 1.20) 0.74 (0.47, 1.16) 0.317 1
CCR7 rs3136685 Intron 1 AA 55 (19.7) 151 (28.3) 1.00 (referent) 1.00 (referent) 0.029 0.031 0.3078
AG 139 (49.8) 237 (44.4) 1.61 (1.11, 2.34) 1.86 (1.18, 2.92) 0.012
GG 85 (30.5) 146 (27.3) 1.60 (1.06, 2.40) 1.39 (0.85, 2.28) 0.024
AG+GG 224 (80.3) 383 (71.7) 1.61 (1.13, 2.28) 1.66 (1.09, 2.54) 0.008 0.599
GG vs (AA+AG) 1.16 (0.85, 1.60) 0.92 (0.62, 1.35) 0.348 0.1615
CCR7 rs3136687 Intron 1 AA 84 (30.1) 173 (32.4) 1.00 (referent) 1.00 (referent) 0.041 0.458 0.3523
AG 153 (54.8) 249 (46.5) 1.26 (0.91, 1.76) 1.45 (0.97, 2.16) 0.161
GG 42 (15.1) 113 (21.1) 0.77 (0.49, 1.19) 0.96 (0.57, 1.62) 0.234
AG+GG 195 (69.9) 362 (67.6) 1.11 (0.81, 1.52) 1.14 (1.12, 1.16) 0.516 0.7159
GG vs (AA+AG) 0.66 (0.45, 0.98) 0.76 (0.49, 1.20) 0.037 0.5092
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the dominant genetic models for the two CCL5 SNPs
(rs2107538, rs3817655) remained significant with false-
discovery rates (FDR) ≤ 0.0150; whereas, the recessive
genetic model for CCR5 rs1799988 was marginally sig-
nificant (FDR = 0.0494).
In an exploratory analysis, we evaluated risk estimates
for all 43 chemokine targets for each racial/ethnic group,
as depicted in Table 3. Among U.S. men, CCR5
rs1799988, CCL5 (rs2107538, rs2280789, rs3817655),
CCL25 rs2032887, and CXCR7 rs1045879 were asso-
ciated with PCA risk. Inheritance of the CCL25
rs2032887 AG+GG (ORunadjusted = 0.66; 95%CI = 0.46,
0.96), CCL5 rs2107538 GA+AA (ORunadjusted = 0.52; 95%
CI = 0.36, 0.76), CCL5 rs2280789 AG+GG (ORunadjusted =
0.60; 95%CI = 0.41, 0.89), and CCL5 rs3817655 GA+AA
(ORunadjusted = 0.46; 95%CI = 0.32, 0.68) genotypes were
significantly associated with a 34-54% reduction in the
risk of developing PCA with chi-square p-values ranging
from 0.0001-0.027. Although the magnitude of the
reduction in PCA risk for CCL5 rs2107538 GA+AA(ORunadjusted = 0.52; ORadjusted = 0.63), CCL5 rs3817655
GA+AA (ORunadjusted = 0.46, ORadjusted = 0.51) and CCL25
rs2032887 AG+GG (ORunadjusted = 0.66, ORadjusted = 0.68)
genotypes remained practically unchanged after adjust-
ing for age, the findings only remained significant for
CCL5 rs33817655 SNP after the adjustment. The
1.54-1.62 fold increase in PCA susceptibility was asso-
ciated with the CCR5 rs1799988 recessive genetic model
(ORunadjusted =1.62; 95%CI=1.08, 2.42) and the CXCR7
rs1045879 AG+GG genotype (ORunadjusted = 1.54;
95%CI = 1.07, 2.22; P = 0.02) was lost in the age adjusted
risk models.
In the Jamaican population, there was a two-fold in-
crease in PCA susceptibility associated with the CCR5
rs1799987 AA (ORunadjusted = 2.18; 95% CI=1.04, 4.58),
CCR5 rs1799988 GG (ORunadjusted =2.25; 95% CI = 1.08,
4.71), and CCR7 rs3136685 AG+GG (ORunadjusted = 2.38;
95% CI = 1.05, 5.07) genotypes, with corresponding chi-
square P-values ranging from 0.02-0.037. Additionally, a
54% reduction in PCA risk was observed for individuals
who possessed the CCR9 rs1488371 CA+AA genotype
Table 3 Association between chemokine associated SNPs and prostate cancer risk, stratified by racial ethnic group
Genes dbSNP ID Location Genotype Unadjusted Unadjusted Age-adjusted Age-adjusted P-value P trend P-vlue P-trend
predicted
function
OR (95%CI) OR (95%CI) OR (95%CI) OR (95%CI) US men US men Jamaican men Jamaican men
US men Jamaican men US men Jamaican men
CCR5 rs1799988 5’UTR AA 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.063 0.076 0.085 0.034
TFBS AG 0.95 (0.62, 1.44) 1.26 (0.66, 2.40) 0.68 (0.42, 1.12) 1.23 (0.60, 2.52) 0.808 0.484
GG 1.58 (0.99, 2.49) 2.25 (1.08, 4.71) 1.06 (0.60, 1.85) 2.23 (0.99, 5.00) 0.053 0.031
AG+GG 1.15 (0.79, 1.68) 1.56 (0.86, 2.82) 0.80 (0.52, 1.26) 1.55 (0.81, 2.98) 0.453 0.142
GG vs
(AA+AG)
1.62 (1.08, 2.42) 1.96 (1.04, 3.70) 1.28 (0.78, 2.12) 1.98 (0.98, 3.98) 0.02 0.037
CCL5 rs2107538 5' near gene GG 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.003 0.002 0.286 0.116
TFBS GA 0.54 (0.36, 0.80) 0.75 (0.40, 1.40) 0.67 (0.42, 1.08) 0.82 (0.40, 1.64) 0.003 0.375
AA 0.48 (0.28, 0.82) 0.53 (0.24, 1.16) 0.53 (0.28, 1.01) 0.52 (0.22, 1.22) 0.007 0.116
AG+AA 0.52 (0.36, 0.76) 0.68 (0.38, 1.23) 0.63 (0.40, 0.99) 0.72 (0.37, 1.40) 0.001 0.204
AA vs
(GG+GA)
0.68 (0.42, 1.11) 0.64 (0.32, 1.26) 0.66 (0.37, 1.20) 0.58 (0.28, 1.24) 0.125 0.192
CCL5 rs2280789 Intron 1 AA 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.039 0.018 0.508 0.823
TFBS AG 0.60 (0.40, 0.90) 1.20 (0.66, 2.18) 0.60 (0.37, 0.97) 1.48 (0.76, 2.89) 0.015 0.549
GG 0.62 (0.24, 1.56) 0.59 (0.18, 1.89) 1.00 (0.34, 2.99) 0.42 (0.12, 1.46) 0.309 0.373
AG+GG 0.60 (0.41, 0.89) 1.06 (0.61, 1.86) 0.64 (0.40, 1.01) 1.18 (0.63, 2.20) 0.011 0.82
GG vs
(AA+AG)
0.72 (0.28, 1.82) 0.55 (0.18, 1.80) 1.14 (1.12, 1.18) 0.36 (0.10, 1.27) 0.488 0.313
CCL5 rs3817655 Intron 2 GG 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0 0.003 0.275 0.11
TFBS GA 0.44 (0.29, 0.65) 0.72 (0.38, 1.34) 0.49 (0.30, 0.80) 0.74 (0.36, 1.50) <0.0001 0.302
AA 0.56 (0.34, 0.92) 0.53 (0.24, 1.16) 0.54 (0.29, 1.02) 0.50 (0.22, 1.20) 0.022 0.115
GA+AA 0.46 (0.32, 0.68) 0.66 (0.36, 1.20) 0.51 (0.32, 0.80) 0.66 (0.34, 1.28) <0.0001 0.167
AA vs
(GG+GA)
0.88 (0.55, 1.40) 0.66 (0.34, 1.28) 0.80 (0.46, 1.42) 0.61 (0.28, 1.27) 0.577 0.22
CCL25 rs2032887 Exon 3 AA 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.084 0.034 0.474 0.379
ESE or ESS AG 0.67 (0.46, 0.99) 1.42 (0.80, 2.48) 0.70 (0.44, 1.11) 1.54 (0.82, 2.88) 0.404 0.225
nsSNP GG 0.61 (0.29, 1.28) 1.10 (0.36, 3.38) 0.57 (0.22, 1.42) 0.84 (0.24, 2.88) 0.196 0.86
probably
damaging
AG+GG 0.66, (0.46, 0.96) 1.37 (0.80, 2.36) 0.68 (0.44, 1.05) 1.42 (0.78, 2.60) 0.027 0.253
missense R>H GG vs
(AA+AG)
0.71 (0.34, 1.47) 0.93 (0.32, 2.75) 0.65 (0.26, 1.60) 0.68 (0.20, 2.24) 0.357 0.898
CCR5 rs1799987 Intron 1 GG 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.197 0.951 0.107 0.041
TFBS GA 1.29 (0.88, 1.92) 1.28 (0.68, 2.44) 0.89 (0.56, 1.44) 1.25 (0.61, 2.56) 0.191 0.442


















Table 3 Association between chemokine associated SNPs and prostate cancer risk, stratified by racial ethnic group (Continued)
GA+AA 1.18 (0.80, 1.70) 1.56 (0.86, 2.82) 0.81 (0.52, 1.26) 1.55 (0.81, 2.98) 0.399 0.142
AA vs
(GG+GA)
0.72 (0.44, 1.21) 1.88 (0.99, 3.56) 0.61 (0.32, 1.15) 1.92 (0.96, 3.88) 0.222 0.051
CCR7 rs3136685 Intron 1 AA 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.381 0.731 0.103 0.086
AG 1.32 (0.86, 2.02) 2.24 (0.98, 5.16) 1.58 (0.94, 2.66) 2.78 (1.09, 7.08) 0.197 0.056
GG 1.07 (0.65, 1.76) 2.38 (1.02, 5.58) 1.02 (0.56, 1.86) 2.52 (0.97, 6.52) 0.778 0.045
AG+GG 1.23 (0.82, 1.84) 2.3 (1.05, 5.07) 1.36 (0.83, 2.21) 2.66 (1.10, 6.42) 0.305 0.037
GG vs
(AA+AG)
0.90 (0.59, 1.36) 1.28 (0.74, 2.25) 0.76 (0.46, 1.26) 1.16 (0.62, 2.15) 0.622 0.372
CCR7 rs3136687 Intron 1 AA 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.022 0.294 0.229 0.218
AG 1.42 (0.89, 2.24) 2.16 (0.84, 5.56) 1.47 (0.85, 2.54) 1.52 (0.53, 4.38) 0.133 0.11
GG 0.78 (0.46, 1.34) 2.20 (0.84, 5.69) 0.85 (0.45, 1.59) 1.34 (0.46, 3.96) 0.38 0.106
AG+GG 1.17 (0.76, 1.81) 2.18 (0.88, 5.38) 1.22 (0.72, 2.05) 1.44 (0.52, 3.98) 0.482 0.092
GG vs (AA+AG) 0.61 (0.40, 0.93) 1.17 (0.68, 2.02) 1.14 (1.12, 1.18) 0.94 (0.51, 1.75) 0.023 0.573
CCR9 rs1488371 Intron 2 CC 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.013 0.902 0.003 0.018
CA 0.94 (0.62, 1.40) 0.52 (0.26, 1.08) 0.88 (0.54, 1.42) 0.60 (0.26, 1.31) 0.747 0.08
AA 1.57 (0.50, 4.90) — 0.92 (0.22, 3.80) — 0.435 0.984
CA+AA 0.98 (0.66, 1.44) 0.46 (0.23, 0.94) 0.88 (0.54, 1.40) 0.48 (0.22, 1.04) 0.901 0.034
AA vs (CC + CA) 1.60 (0.52, 4.97) — 0.95 (0.23, 4.00) — 0.414 0.984
CXCR7 rs1045879 Exon 1 AA 1.00 (referent) 1.00 (referent) 1.00 (referent) 1.00 (referent) 0.065 0.038 0.459 0.762
synSNP AG 1.54 (1.06, 2.26) 1.38 (0.77, 2.48) 1.30 (0.82, 2.04) 1.30 (0.68, 2.50) 0.025 0.279
L>L GG 1.53 (0.84, 2.79) 0.86 (0.34, 2.16) 1.02 (0.47, 2.20) 0.74 (0.27, 2.04) 0.166 0.756
AG+GG 1.54 (1.07, 2.22) 1.24 (0.72, 2.14) 1.24 (0.80, 1.93) 1.15 (0.62, 2.10) 0.02 0.431
GG vs (AA+AG) 1.21 (0.69, 2.13) 0.76 (0.31, 1.84) 0.88 (0.42, 1.84) 0.67 (0.25, 1.80) 0.499 0.538
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markers, the CCR7 rs3136685 SNP remained significant
after adjusting for age. Notably, the magnitude of PCA
risk estimates did not change for the CCR5, CCL5, and
CCR9 SNPs, comparing the adjusted and unadjusted risk
models.
Discussion
Chemotaxis is an important process required for tumor
growth and metastasis. It is regulated by a complex net-
work of chemokines, chemokine receptors and down-
stream targets that synergistically regulate immune and
inflammatory responses. Recent molecular studies have
demonstrated that over expression of selected chemo-
kines and chemokine receptors are related to aggressive
cancer phenotypes, including lung, breast and prostate
cancer. Some observational studies suggest inheritance
of susceptibilities detected in chemokine associated
genes may alter the risk of developing cancer. However,
to our knowledge, there are no published reports on the
impact of inheriting multiple functional variants in rela-
tion to prostate cancer among men of African Descent.
Therefore, the current study evaluated the individual
effects of 43 chemokine associated sequence variants on
PCA risk among 279 cases and 535 disease-free men of
African descent from the U.S and Jamaica. Five SNPs
detected in CCL5, CCR5 and CCR7 were significantly
associated with prostate cancer risk among all study par-
ticipants; however, only three markers survived adjust-
ments for potential confounders and multiple hypothesis
testing. Notably, inheritance of at least one CCL5
rs3817655 A or CCL5 rs2107538 A loci was linked with
a 34-44% decrease in PCA susceptibility among all men
of African Descent. In addition, the recessive genetic
model for CCR5 rs1799988 was associated with a 52-
73% increase in PCA risk. We also observed significant
main effects for the CCL5 rs3817655 and CCR7
rs3136685 SNPs among U.S. and Jamaican men, respect-
ively. Further discussion will be restricted to the more
robust SNPs detected in CCL5 and CCR5.
Several cancer cells, including PCA cells, express che-
mokines and their cell surface bound receptors. Chemo-
kine ligand 5 (RANTES), is a small molecule with a
strong capacity to induce cellular migration of inflam-
matory cells and production of its receptor (CCR5) in
human PCA cell lines [13,32]. The CCL5/CCR5 axis
induces PCA cell proliferation and cell invasion. It’s
speculated that once CCL5 binds to CCR5, it serves as
an autocrine factor and activates cellular responses
involved in cancer progression [13]. In the current study,
possession of the CCL5 rs3817655 A or CCL5 rs2107538
A loci was linked with a protective effect in relation to
prostate cancer risk among all men of African descent
from the U.S. and Jamaica combined. The directionalityof the risk estimates persisted when we stratified by
racial/ethnic group; however, the findings were only statis-
tically significant for the U.S. men. In addition, findings
for the total and U.S. subgroups remained significant
even after adjusting for age and multiple hypothesis test-
ing. The observed protective effects associated with the
two aforementioned CCL5 SNPs (rs3817655, rs2107538)
may be attributed to a reduction in transcriptional acti-
vation, reduced protein levels, and ultimately reduced
tumorigenic capacity. To our knowledge, there are no
published reports on the impact of the CCL5 rs3817655
SNP on prostate cancer susceptibility or its functional
consequence on genes/proteins. On the other hand, the
CCL5 rs2107538 G-403A promoter SNP is associated
with a decrease in protein expression detected in serum
collected from Type II diabetic and disease-free subjects
[16]. In addition, this locus has been evaluated in two in-
dependent prostate cancer studies. In a study involving
607 Caucasian male residents of Spain (297 cases, 3011
controls), Saenz-Lopez and co-workers (2008) observed
a 1.44-fold increase in PCA risk among carriers of the
CCL5 rs2107538 GA+AA genotype (P = 0.039) [18].
However, this finding did not corroborate with a larger
null report consisting of 1553 Caucasian men (i.e., 815
PCA cases, 738 controls) from Australia [33]. Our find-
ings of a protective effect against PCA among our study
participants is consistent with other published reports
that reveal a decrease in the risk of developing gastric
cancer, lymphoma, and type 1 diabetes [10,16,20].
Within a multi-ethnic pancreatic case–control study, the
prevalence of the “A” allele was more frequent among
disease-free Asian and African-Americans relative to
pancreatic cases [23]. However, this allele was more
prevalent among Caucasian pancreatic cases relative to
controls. Collectively, these findings may suggest inherit-
ance of genetic susceptibilities detected in the CCL5
gene may vary across different racial/ethnic groups.
The functional impact of CCL5 sequence variants is
complicated by the high degree of linkage disequilibrium
within both the promoter and intron 1 region. An and
co-workers (2006), evaluated the impact of three SNPs
detected in the promoter region (rs2280788 -28C/G,
rs2107538 -405 G/A) and intron 1 of CCL5 rs2280789
[17]. They demonstrated that transcriptional regulation
of CCL5 was primarily governed by an intron 1.1 A/G
SNP (rs2280789). Intron 1.1 G allele corresponded with
a strong decrease in transcriptional activity of RANTES;
whereas, the -28G allele had a modest up-regulation in
human cell lines. In our stratified analysis, the intron 1.1
CCL5 rs2280789 AG or AG+GG genotypes were asso-
ciated with a marginal 36-41% decrease in PCA risk
among men of African descent from the US; however,
these findings require further evaluation in a larger study
set. The CCL5 rs2280788-28 C/G SNP was not evaluated
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for African-American men, as reported in NCBI. The
functional consequence of CCL5 SNPs is further per-
plexed by their interaction with downstream receptors.
The biological activity mediated by CCL5 is facilitated
through its interaction with chemokine receptors (CCR1,
CCR2, CCR3, and CCR5). However, relative to CCR1-3,
CCR5 plays a more important role in CCL5-mediated
cell migration [34]. CCR5, a member of the beta chemo-
kine receptor family, is a seven transmembrane protein,
which is expressed by T cells and macrophages. Over ex-
pression of CCR5 has been detected in aggressive pros-
tate cancer tissue relative to benign prostatic hyperplasia
[32]. The CCR5 rs1799988 C allele is significantly asso-
ciated with viral load set point (i.e., decreased time from
asymptomatic HIV+ to AIDS and increased infectious-
ness) and AIDS progression [35]. However, there are no
published reports for this 5’UTR SNP in relation to pros-
tate cancer or other inflammatory/immune response-
related diseases. In the current study, we observed a
1.52-1.75 fold increase in the risk of developing prostate
cancer among all men of African descent who possessed
the CCR5 rs1799988 CC genotype. However, the impact
of this SNP in relation to PCA risk was more pro-
nounced among men of African descent from Jamaica
relative to U.S. men. This increased risk may have an im-
pact on transcriptional activity, which may result in
increased protein levels of CCR5; however, this requires
confirmation using ex vivo, in vitro, and micro-dissected
tumor tissue-based assays.
The strengths, limitations and future directions of
this study were considered. Forty-three sequence var-
iants were evaluated in relation to prostate cancer risk
among men of African descent from the U.S. and Ja-
maica. A strong correlation between the minor allele
frequencies between these two study populations
enabled us to pool genetic data to identify relationships
that would have remained undetected if we evaluated
the populations separately. As a result of pooling, we
identified three SNPs (i.e., CCL5 rs3817655, CCL5
rs2107538, CCR5 rs1799988) that were significantly
associated with prostate cancer in the total population
even after adjusting for age and multiple hypothesis
testing. Upon stratification by study center, we cannot
rule out the possibility that race/ethnic specific se-
quence variants may track with disease progression or
prognosis. Consequently, future targeted sequencing
will allow us to identify, evaluate and validate novel
and commonly reported chemokine-associated SNPs as
tumor classification and prognostication tools among
African-American, Caribbean, African and European
men. Such efforts will require pooled data from multi-
center studies that seek to identify the genetic sig-
natures related to prostate cancer health disparitiesdomestically and globally. In addition, molecular bio-
logical studies are needed to understand the functional
consequence of the CCL5 and CCR5 sequence variants
on: mRNA expression/stability, or protein expression,
structure and/or function. This will require well anno-
tated observational studies that allow us to consider
lifestyle, geographical, environmental, or cultural differ-
ences that may interact with genetic susceptibilities and
subsequently modify PCA outcomes. In future studies,
we will determine the impact of coding and non-
coding SNPs on mRNA and protein levels in tissue col-
lected from men of African and European descent
using ex vivo, in vitro, and tissue-based assays. Lastly,
study participants in the current study self-identified
themselves as African-American, Caribbean, African, or
Jamaican. Population admixture, which commonly
occurs among men of African descent, may bias risk
estimates. After adjusting risk estimates for West
African Ancestry, risk estimates did not significantly
vary when compared to unadjusted risk models (data
not shown). In the current study, we had greater than
80% statistical power to observe effect sizes of ≥ 1.5
(or ≤ 0.67) and 1.55 (or ≤ 0.64) for the total and U.S.
populations, respectively. All p-values in the current
study were adjusted for multiple hypotheses testing to
minimize false positive results using the false discovery
rate. Despite these efforts, we cannot rule out the pos-
sibility that the significant relationships observed for
the U.S. (CCL5 rs3817655) and total populations
(CCL5 rs2107538, CCL5 rs3817655, CCR5 rs1799988)
are suggestive and warrant further validation in larger
studies. Future studies in our laboratory will focus on
high-throughput targeted sequencing to evaluate the
impact of novel and commonly reported CCL5
(rs2107538, CCL5 rs3817655) and CCR5 (rs1799988)
sequence variants on PCA susceptibility and disease
prognosis among men of African descent. Even modest
variations in genotype allele frequencies among men of
African descent can reduce the chances of replicating
single SNP effects within and between independent and
validation study sets. To ensure reproducibility within
future and ongoing studies, extreme care is needed to
select study sets with comparable ancestry and genetic
backgrounds.
Conclusions
Our preliminary findings suggest that CCL5 (rs2107538,
rs3817655) and CCR5 (rs1799988) SNPs may modify
PCA susceptibility among men of African descent in the
current study. In larger ongoing studies, we will evaluate
the impact of individual or combination of chemokine-
associated SNPs in relation to prostate cancer risk,
tumor grade, biochemical or disease recurrence, and
mortality. Such efforts will help to identify genetic
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prostate cancer incidence, mortality, and morbidity rates
among men of African descent.
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